PDF(Pubmed)
Abstract：
UNASSIGNED: Staphylococcus aureus is the leading cause of death due to bacterial bloodstream infection. Female sex has been identified as a risk factor for mortality in S aureus bacteremia (SAB) in some studies, but not in others.
UNASSIGNED: To determine whether female sex is associated with increased mortality risk in SAB.
UNASSIGNED: MEDLINE, Embase, and Web of Science were searched from inception to April 26, 2023.
UNASSIGNED: Included studies met the following criteria: (1) randomized or observational studies evaluating adults with SAB, (2) included 200 or more patients, (3) reported mortality at or before 90 days following SAB, and (4) reported mortality stratified by sex. Studies on specific subpopulations (eg, dialysis, intensive care units, cancer patients) and studies that included patients with bacteremia by various microorganisms that did not report SAB-specific data were excluded.
UNASSIGNED: Data extraction and quality assessment were performed by 1 reviewer and verified by a second reviewer. Risk of bias and quality were assessed with the Newcastle-Ottawa Quality Assessment Scale. Mortality data were combined as odds ratios (ORs).
UNASSIGNED: Mortality at or before 90-day following SAB, stratified by sex.
UNASSIGNED: From 5339 studies retrieved, 89 were included (132 582 patients; 50 258 female [37.9%], 82 324 male [62.1%]). Unadjusted mortality data were available from 81 studies (109 828 patients) and showed increased mortality in female patients compared with male patients (pooled OR, 1.12; 95% CI, 1.06-1.18). Adjusted mortality data accounting for additional patient characteristics and treatment variables were available from 32 studies (95 469 patients) and revealed a similarly increased mortality risk in female relative to male patients (pooled adjusted OR, 1.18; 95% CI, 1.11-1.27). No evidence of publication bias was encountered.
UNASSIGNED: In this systematic review and meta-analysis, female patients with SAB had higher mortality risk than males in both unadjusted and adjusted analyses. Further research is needed to study the potential underlying mechanisms.
UNASSIGNED: To determine whether female sex is associated with increased mortality risk in SAB.
UNASSIGNED: MEDLINE, Embase, and Web of Science were searched from inception to April 26, 2023.
UNASSIGNED: Included studies met the following criteria: (1) randomized or observational studies evaluating adults with SAB, (2) included 200 or more patients, (3) reported mortality at or before 90 days following SAB, and (4) reported mortality stratified by sex. Studies on specific subpopulations (eg, dialysis, intensive care units, cancer patients) and studies that included patients with bacteremia by various microorganisms that did not report SAB-specific data were excluded.
UNASSIGNED: Data extraction and quality assessment were performed by 1 reviewer and verified by a second reviewer. Risk of bias and quality were assessed with the Newcastle-Ottawa Quality Assessment Scale. Mortality data were combined as odds ratios (ORs).
UNASSIGNED: Mortality at or before 90-day following SAB, stratified by sex.
UNASSIGNED: From 5339 studies retrieved, 89 were included (132 582 patients; 50 258 female [37.9%], 82 324 male [62.1%]). Unadjusted mortality data were available from 81 studies (109 828 patients) and showed increased mortality in female patients compared with male patients (pooled OR, 1.12; 95% CI, 1.06-1.18). Adjusted mortality data accounting for additional patient characteristics and treatment variables were available from 32 studies (95 469 patients) and revealed a similarly increased mortality risk in female relative to male patients (pooled adjusted OR, 1.18; 95% CI, 1.11-1.27). No evidence of publication bias was encountered.
UNASSIGNED: In this systematic review and meta-analysis, female patients with SAB had higher mortality risk than males in both unadjusted and adjusted analyses. Further research is needed to study the potential underlying mechanisms.
摘要：
■金黄色葡萄球菌是细菌血流感染导致死亡的主要原因。在一些研究中，女性已被确定为金黄色葡萄球菌菌血症（SAB）死亡的危险因素，但不是在别人。
■确定女性是否与SAB的死亡风险增加有关。
■MEDLINE,Embase,和WebofScience从成立到2023年4月26日进行了搜索。
■纳入的研究符合以下标准：（1）评估成人SAB的随机或观察性研究，（2）包括200名以上的患者，（3）在SAB后90天或之前报告的死亡率，(4)按性别分层的报告死亡率。对特定亚群的研究(如，透析,重症监护病房,癌症患者）和包括未报告SAB特异性数据的各种微生物菌血症患者的研究被排除。
■数据提取和质量评估由1名评审员进行，并由第二名评审员进行验证。使用纽卡斯尔-渥太华质量评估量表评估偏倚和质量的风险。死亡率数据合并为比值比(ORs)。
■SAB后90天或之前的死亡率，按性别分层。
■从检索到的5339项研究中，包括89例（132582例患者；50258例女性[37.9%]，82324男性[62.1%]）。81项研究（109828例患者）提供了未经调整的死亡率数据，显示女性患者死亡率高于男性患者（合并OR，1.12；95%CI，1.06-1.18）。从32项研究（95469例患者）中获得了考虑其他患者特征和治疗变量的调整后死亡率数据，并揭示了女性相对于男性患者的死亡率风险相似增加（合并的调整后OR，1.18；95%CI，1.11-1.27）。没有遇到发表偏倚的证据。
■在本系统综述和荟萃分析中，在未经校正和校正的分析中,女性SAB患者的死亡风险高于男性.需要进一步的研究来研究潜在的潜在机制。
■确定女性是否与SAB的死亡风险增加有关。
■MEDLINE,Embase,和WebofScience从成立到2023年4月26日进行了搜索。
■纳入的研究符合以下标准：（1）评估成人SAB的随机或观察性研究，（2）包括200名以上的患者，（3）在SAB后90天或之前报告的死亡率，(4)按性别分层的报告死亡率。对特定亚群的研究(如，透析,重症监护病房,癌症患者）和包括未报告SAB特异性数据的各种微生物菌血症患者的研究被排除。
■数据提取和质量评估由1名评审员进行，并由第二名评审员进行验证。使用纽卡斯尔-渥太华质量评估量表评估偏倚和质量的风险。死亡率数据合并为比值比(ORs)。
■SAB后90天或之前的死亡率，按性别分层。
■从检索到的5339项研究中，包括89例（132582例患者；50258例女性[37.9%]，82324男性[62.1%]）。81项研究（109828例患者）提供了未经调整的死亡率数据，显示女性患者死亡率高于男性患者（合并OR，1.12；95%CI，1.06-1.18）。从32项研究（95469例患者）中获得了考虑其他患者特征和治疗变量的调整后死亡率数据，并揭示了女性相对于男性患者的死亡率风险相似增加（合并的调整后OR，1.18；95%CI，1.11-1.27）。没有遇到发表偏倚的证据。
■在本系统综述和荟萃分析中，在未经校正和校正的分析中,女性SAB患者的死亡风险高于男性.需要进一步的研究来研究潜在的潜在机制。
